What Is Biktarvy Used For? FDA Indications, How It Works, and 5-Year Clinical Data

Biktarvy is the most widely prescribed HIV medication in the United States. But the question patients most often arrive with isn’t whether it works — it’s a more fundamental one: what is it actually for, and will it work for me?

This page answers that completely. It covers every FDA-approved indication including the July 2025 expansion, exactly how the drug works inside the body, who qualifies and who should not take it, and what five years of clinical data actually shows — including the resistance finding that no earlier HIV regimen has matched.

What Is Biktarvy?

Biktarvy (bictegravir/emtricitabine/tenofovir alafenamide) is a once-daily, single-tablet, complete HIV-1 treatment regimen developed by Gilead Sciences and first approved by the US FDA on February 7, 2018. It is a complete regimen in a single pill — one tablet, once daily, with or without food, is the entire treatment.

The combination is referred to as B/F/TAF or BIC/FTC/TAF in clinical literature. A lower-dose pediatric tablet (BIC 30 mg / FTC 120 mg / TAF 15 mg) is approved for children weighing 14–25 kg.

FDA-Approved Indications (All, Including July 2025)

Biktarvy’s FDA label has been expanded five times since its 2018 approval. As of 2026, it covers six distinct patient populations — more than any other single-tablet HIV regimen currently available.

Switching from another regimen

Adults already on a stable HIV regimen can switch to Biktarvy without a washout period, provided their viral load has been below 50 copies/mL for at least three months, they have no known resistance to any of Biktarvy’s components, and they are not taking contraindicated medications. Switch studies (GS-US-380-1878 and GS-US-380-1844) demonstrated virologic suppression was maintained in over 97% of patients following the switch.

How Biktarvy Works Inside the Body

HIV replicates through a defined sequence of steps. Biktarvy’s three components block that sequence at two separate checkpoints — which is why resistance to all three simultaneously is so clinically rare.

Step 1 — HIV enters the CD4 cell

The virus binds to CD4 and co-receptors on the T cell surface, fuses with the cell membrane, and injects its RNA genome and replication enzymes into the host cytoplasm. Biktarvy does not act at this step.

Step 2 — Reverse transcription, blocked by FTC and TAF

HIV’s reverse transcriptase converts viral RNA into DNA using natural nucleoside building blocks. Emtricitabine (FTC) and tenofovir alafenamide (TAF) mimic those building blocks and get incorporated into the growing chain — but they lack the chemical group needed to continue extension, so the chain terminates and DNA synthesis stops before it can complete.

Step 3 — Integration, blocked by BIC

Any viral DNA that escapes the reverse transcription blockade must be inserted into the host chromosome by the viral integrase enzyme. Bictegravir (BIC) chelates the magnesium ions in the integrase active site, blocking strand transfer entirely. Without successful integration, HIV cannot produce new proteins, assemble new virions, or infect additional cells.

Step 4 — Viral load falls toward undetectable

With both checkpoints blocked, active HIV replication ceases. Plasma viral load typically falls below 50 copies/mL within 24–48 weeks in treatment-naïve patients. The immune system stabilizes and CD4 count recovers.

Why TAF instead of TDF?

Tenofovir alafenamide (TAF) is a prodrug that activates inside cells rather than in the bloodstream, reaching effective intracellular concentrations at a much lower oral dose than tenofovir disoproxil fumarate (TDF). The result is significantly lower plasma tenofovir exposure — and the reason Biktarvy shows better kidney and bone safety markers than TDF-containing regimens in five-year trials.

Why is resistance so rare?

HIV mutates rapidly. Using three agents from two drug classes means the virus would need to simultaneously develop mutations defeating all three mechanisms. Bictegravir also has a higher genetic barrier to resistance than first-generation integrase inhibitors like raltegravir, meaning partial mutations are insufficient to compromise it. In five years of clinical trials across hundreds of patients, this combination produced zero cases of treatment-emergent resistance.

Who Can Take Biktarvy — and Who Should Not

5-Year Clinical Data — What the Trials Show

Studies 1489 and 1490 were Phase 3 randomized trials comparing Biktarvy to dolutegravir-based regimens in treatment-naïve adults. Results at Week 240 were published in eClinicalMedicine (The Lancet journal family) in 2023 — the most complete long-term efficacy dataset for any single-tablet HIV regimen currently available.

Understanding the two suppression figures

The 98.6% is an observed analysis — the proportion of patients still in the trial at Week 240 who had undetectable viral loads. The 67.2% uses intent-to-treat methodology, counting every patient who enrolled — including those lost to follow-up, who withdrew for non-drug reasons, or who died of unrelated causes — as treatment failures. The 98.6% answers does it work in patients who take it? The 67.2% answers of everyone who enrolled, how many were still suppressed five years later?

What Biktarvy Does Not Do

Biktarvy does not cure HIV

No approved antiretroviral eliminates the latent HIV reservoir. Biktarvy suppresses viral replication to undetectable levels, but HIV DNA persists in long-lived CD4 cells. If Biktarvy is stopped, viral rebound typically occurs within two to eight weeks in most patients.

Biktarvy is not a preventive medication (PrEP or PEP)

Biktarvy is a treatment for people already living with HIV-1. HIV-negative individuals seeking prevention should discuss FDA-approved PrEP options with a provider — options include Truvada (FTC/TDF) and Descovy (FTC/TAF). Biktarvy has not been studied for and is not approved for pre- or post-exposure prophylaxis.

Undetectable does not mean HIV is gone

“Undetectable” means HIV RNA is below the assay threshold (typically 20–50 copies/mL). The U=U framework (Undetectable = Untransmittable) is based on evidence that undetectable viral load during consistent treatment eliminates sexual transmission risk — not on the premise that the virus has been eliminated.

Biktarvy does not treat HIV-2

HIV-2 is a distinct viral species with different virological characteristics. Clinical data for Biktarvy in HIV-2 is absent. Patients with HIV-2 require a separately tailored regimen under expert guidance.

Dosing & Key Drug Interactions

Biktarvy is taken as one tablet orally once daily, with or without food. Consistency matters more than the specific hour — the long half-life of bictegravir (approximately 17–19 hours) provides a pharmacokinetic buffer against minor timing variations. Consecutive missed days, however, risk viral rebound.

Frequently Asked Questions